Press Releases

Date Title
Toggle Summary Kura Oncology Reports Third Quarter 2018 Financial Results and Provides Corporate Update
– Registration-directed trial of tipifarnib in HRAS mutant HNSCC now underway – – Encouraging preliminary clinical activity observed in HRAS mutant SCC cohort – – Preliminary data from AITL and CXCL12+ cohorts in Phase 2 trial of tipifarnib in PTCL upcoming at ASH – – $187.4 million in cash, cash
Toggle Summary Kura Oncology Initiates Registration-Directed Trial of Tipifarnib in HRAS Mutant Head and Neck Squamous Cell Carcinomas
– AIM-HN designed to enroll at least 59 patients with HRAS mutant HNSCC – – Full enrollment expected in two years with response rate as primary endpoint – SAN DIEGO , Nov. 05, 2018 (GLOBE NEWSWIRE) --   Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the
Toggle Summary Kura Oncology Announces Upcoming Presentations at ASH Annual Meeting
SAN DIEGO , Nov. 01, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that two abstracts related to the company’s lead product candidate, tipifarnib, have been
Toggle Summary Kura Oncology to Report Third Quarter 2018 Financial Results
SAN DIEGO , Oct. 29, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that it will report third quarter 2018 financial results after the close of U.S.
Toggle Summary Kura Oncology Presents Update on Positive Phase 2 Trial of Tipifarnib in HRAS Mutant HNSCC and Preliminary Results in HRAS Mutant SCC
– Nine patients with HRAS mutant HNSCC experienced tumor size reductions, including six confirmed PRs and two patients with disease stabilization greater than six months – – One additional HNSCC patient dosed outside protocol with an unconfirmed PR – – Six patients enrolled in additional cohort of
Toggle Summary Kura Oncology to Present at Leerink Partners Rare Disease & Oncology Roundtable
SAN DIEGO , Sept. 26, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced that Troy Wilson , Ph.D., J.D., Kura’s President and Chief Executive Officer, is scheduled to
Toggle Summary Kura Oncology to Present at H.C. Wainwright Global Investment Conference
SAN DIEGO , Aug. 30, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced its participation at the H.C. Wainwright 20 th Annual Global Investment Conference .
Toggle Summary Kura Oncology to Present at 2018 Wedbush PacGrow Healthcare Conference
SAN DIEGO , Aug. 07, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today announced its participation at the 2018 Wedbush PacGrow Healthcare Conference .
Toggle Summary Kura Oncology Reports Second Quarter 2018 Financial Results and Provides Corporate Update
– Update from ongoing Phase 2 trial of tipifarnib in HRAS mutant head and neck squamous cell carcinomas (HNSCC) to be presented at ESMO 2018 – – Startup activities initiated for upcoming registration-directed trial of tipifarnib in HRAS mutant HNSCC – – Biomarker-enriched Phase 2 trial of
Toggle Summary Kura Oncology Appoints Marc Grasso, M.D., as Chief Financial Officer and Chief Business Officer
Investment banking veteran brings two decades of experience in finance and corporate strategy in the biopharma industry SAN DIEGO , July 31, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for